PMEF
RVNC

Point72 Middle East FZE’s Revance Therapeutics, Inc. RVNC Stock Holding History

Point72 Middle East FZE’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-74,330
Closed -$653K – 1412
2023
Q4 		$653K Buy
74,330
+72,245
+3,465% +$592K 0.02% 737
2023
Q3 		$23.9K Sell
2,085
-31,655
-94% -$609K ﹤0.01% 1306
2023
Q2 		$854K Buy
+33,740
New +$1.05M 0.02% 633
2023
Q1 		– Sell
-8,048
Closed -$149K – 2311
2022
Q4 		$149K Buy
+8,048
New +$184K 0.01% 1149

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Middle East FZE's RVNC Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2024, closing a stake of 74,330 shares — an estimated $653K sold.

Point72 Middle East FZE first reported a position in RVNC in Q4 2022 and held it in 4 quarters. The position peaked at $854K in Q2 2023. 188 funds tracked by Wall St. Rank hold RVNC as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Revance Therapeutics, Inc. position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 74,330 Revance Therapeutics, Inc. shares in Q1 2024, an estimated $653K.
  • Point72 Middle East FZE first reported a position in Revance Therapeutics, Inc. in Q4 2022 and held it in 4 quarters.
  • Point72 Middle East FZE's Revance Therapeutics, Inc. position peaked at $854K in Q2 2023.
  • 188 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.